Comparison of antifungal sensitivity profile of multiresistant emerging yeast isolates Candida auris recovered from fungemias, candidiasis and colonization processes in Colombia.

Project: Research project

Project Details


On the occasion of the "Global Emergency Alert for Invasive Infections Caused by Multidrug Resistant Yeast Candida auris", issued by the National Institute of Health in September 2016, approximately 120 clinical isolates associated with different forms of presentation of the infection have been received, including fungemia, candidiasis or colonization by multidrug-resistant yeast C. auris. One of the characteristics of this yeast is its multiresistance; some isolates of C. auris present minimum inhibitory concentrations (MIC) elevated to the three main classes of antifungals, limiting the therapeutic options. In Colombia, preliminary studies indicate that in Colombia, strains of this yeast with elevated MIC values circulate to the most used antifungal treatments: fluconazole and amphotericin B.
Outbreaks have been characterized in at least 4 medical institutions in three departments of the country, with a mortality superior to 50%, in patients with a wide range of age; the characterization of these outbreaks has allowed to recover the yeast of the hospital environment, indicating that this pathogen has the capacity to contaminate the environment close to the patient, becoming a microorganism of high importance in the group of those involved in the IAAS.
Currently, it is evident that C. auris has emerged as an important nosocomial pathogen, transmitted inter and intra-hospitalally in a clonal manner, widely dispersed in different regions of the world, associated with high mortality, therapeutic failure and resistance to several classes of antifungal agents.
Determining the sensitivity profile of clinical isolates of C. auris to an ample panel of antifungal agents is of great importance considering the multiresistance capacity of this yeast, as well as establishing whether there are differences in the sensitivity of the strains according to their association with fungemia or candidiasis, in order to give timely management and treatment to patients, consequently reducing the very high morbidity and mortality.

Translated with
Effective start/end date5/20/195/20/20

Main Funding Source

  • Internal